Orthocell shareholders approve resolutions, re-elect director

Orthocell Limited (ASX: OCC) announced today the results of its Annual General Meeting held on November 6, 2025, with all resolutions carried by shareholders on a poll. Key approvals included the re-election of michael mcnulty as a director, the Employee Awards Plan, and an increase in non-executive directors’ cash fees. Shareholders also approved the issue of fee shares to john van der wielen, dr. ravi thadhani, professor fiona wood AM, and michael mcnulty.

A significant outcome was the approval of Resolution 9, an amendment to the Company's Constitution, which was carried as a special resolution. This amended Constitution, adopted on October 31, 2023, and further amended by special resolution on November 6, 2025, governs various aspects of the company's operations.

The company also disclosed proxy votes for each resolution, demonstrating strong shareholder support, with most resolutions receiving over 70% of votes in favor. The updated constitution reflects the governance framework under which Orthocell, a regenerative medicine company, operates as it advances its portfolio of collagen medical devices and cell therapies.